Silence Therapeutics (SLN) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Silence Therapeutics has unveiled promising Phase 2 trial results for its siRNA treatment, zerlasiran, showing significant reductions in lipoprotein(a) levels in patients with cardiovascular disease. The data, presented at the American Heart Association Annual Meeting and published in JAMA, highlight an over 80% reduction in Lp(a) with infrequent dosing post-treatment, paving the way for Phase 3 trials. With elevated Lp(a) affecting a significant portion of the population and linked to serious health risks, zerlasiran could offer a groundbreaking solution for those affected.
For further insights into SLN stock, check out TipRanks’ Stock Analysis page.